Highs, lows of psychedelics research wrapped in first-time UCSF trial


Psychedelic drug research faces stigma, bias and basic research questions, let alone regulatory and business model concerns.

Previous Ascension converts St. Francis unit to serve cardiothoracic patients
Next Q&A: Philadelphia-based American Cancer Society CEO Karen Knudsen on her 'incredible' first year